TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39490799

Group type: EXPERIMENTAL
Intervention: Quadruple-fortified salt (QFS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Double-fortified salt (DFS)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Iodized salt
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Salt type (QFS, DFS, iodized salt)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Overall intervention period
Number of subjects: 77
Study: 39490969

Group type: EXPERIMENTAL
Intervention: Serum antiglycopeptidolipid core IgA antibody test
Number of subjects: 282
Study: 39490971

Group type: EXPERIMENTAL
Intervention: Modified Medical Research Council (mMRC) scale
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Incremental cardiopulmonary cycle exercise testing (CPET)
Number of subjects: 318
Study: 39490985

Group type: EXPERIMENTAL
Intervention: Hypotension-avoidance strategy (target intraoperative MAP 80 mm Hg or over, hold renin-angiotensin-aldosterone system inhibitors on day of surgery and for two days after)
Number of subjects: 7307

Group type: COMPARATOR
Intervention: Hypertension-avoidance strategy (target intraoperative MAP 60 mm Hg or more, continue all antihypertensives before and after surgery)
Number of subjects: 7307
Study: 39491057

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Exercise (females)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study: 39491310

Group type: EXPERIMENTAL
Intervention: ERT16 (16-session emotion regulation therapy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: ERT8 (8-session emotion regulation therapy)
Number of subjects: 72
Study: 39491396

Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily (adjusted for crossover)
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study: 39491572

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy with the ClotTriever System
Number of subjects: 300

Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 300
Study: 39491599

Group type: EXPERIMENTAL
Intervention: Phage therapy (172 pharmaceutical phage cocktails targeting Staphylococcus aureus and/or Pseudomonas aeruginosa; 57 for local injection and 99 for intravenous injection)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Phage therapy
Number of subjects: 33
Study: 39491719

Group type: EXPERIMENTAL
Intervention: Ultraviolet photography, MC1R genetic testing, and action planning (each with two levels: yes v. no)
Number of subjects: 528
Study: 39491831

Group type: EXPERIMENTAL
Intervention: Saliva samples from periodontitis patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Saliva samples from CRC patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CRC resection material from CRC patients
Number of subjects: 18
Study: 39491870

Group type: EXPERIMENTAL
Intervention: Early DOAC initiation (≤4 days from stroke symptom onset)
Number of subjects: 3621

Group type: COMPARATOR
Intervention: Delayed DOAC initiation (7-14 days)
Number of subjects: 3621
Study: 39491902

Group type: EXPERIMENTAL
Intervention: Transcranial focused ultrasound (tfUS) targeting the right amygdala, 10-min sessions, 8 weekly sessions
Number of subjects: 25
Study: 39491945

Group type: EXPERIMENTAL
Intervention: Midazolam nasal spray (MDZ-NS) 5 mg administered for seizure clusters, with a second 5 mg dose possible if seizures did not terminate within 10 min or recurred within 10 min-6 h.
Number of subjects: 161
Study: 39492050

Group type: EXPERIMENTAL
Intervention: Olaparib plus Abiraterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus Abiraterone
Number of subjects: 0
Study: 39492125

Group type: EXPERIMENTAL
Intervention: PIFU and asynchronous telemedicine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 39492363

Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL) as adjunctive treatment in coronary angioplasty
Number of subjects: 500
Study: 39492485

Group type: EXPERIMENTAL
Intervention: Longer fasting durations
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Early morning food consumption
Number of subjects: 95
Study: 39492655

Group type: EXPERIMENTAL
Intervention: Mobile application follow-up
Number of subjects: 80
Study: 39492702

Group type: EXPERIMENTAL
Intervention: Ultrathin DES
Number of subjects: 1367

Group type: COMPARATOR
Intervention: Thin-strut DES
Number of subjects: 1367
Study: 39492703

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 70
Study: 39492701

Group type: EXPERIMENTAL
Intervention: Tailored antiplatelet therapy (early escalation with low-dose ticagrelor at 60 mg twice daily plus aspirin for <6 months, followed by late de-escalation to clopidogrel monotherapy for >6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin for 12 months
Number of subjects: 0
Study: 39492841

Group type: EXPERIMENTAL
Intervention: cadonilimab at a dosage of 6 mg/kg on day 1 of each 21-day cycle combined with intravenous liposomal irinotecan at a dosage of 70 mg/m2
Number of subjects: 51
Study: 39492851

Group type: EXPERIMENTAL
Intervention: Expanded CHW model
Number of subjects: 2886

Group type: COMPARATOR
Intervention: Existing CHW model
Number of subjects: 2886
Study: 39493113

Group type: EXPERIMENTAL
Intervention: Cone beam CT (CBCT)-based online adaptive radiotherapy (OART)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Conventional stereotactic body radiotherapy (SBRT)
Number of subjects: 1
Study: 39493261

Group type: EXPERIMENTAL
Intervention: Colonoscopy with CADe + ECV
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Colonoscopy with CADe
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 90
Study: 39493359

Group type: EXPERIMENTAL
Intervention: Smartwatch + cardiac patch monitor
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cardiac patch monitor only
Number of subjects: 95
Study: 39493410

Group type: EXPERIMENTAL
Intervention: Hybrid telemedicine approach with in-person follow-ups
Number of subjects: 46

Group type: COMPARATOR
Intervention: Face-to-face visits
Number of subjects: 46
Study: 39493541

Group type: EXPERIMENTAL
Intervention: Antenatal breastmilk expression (aBME)
Number of subjects: 7
Study: 39493627

Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation (TR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional rehabilitation (CT)
Number of subjects: 55
Study: 39493634

Group type: EXPERIMENTAL
Intervention: Physical exercise programme guided by the COVIDReApp system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paper format exercise programme
Number of subjects: 100
Study: 39493729

Group type: EXPERIMENTAL
Intervention: Frequent error augmentation physical therapy (F-EA-PT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard-of-care physical therapy (SOC-PT)
Number of subjects: 100
Study: 39493888

Group type: EXPERIMENTAL
Intervention: guselkumab (100 mg every 4 weeks (Q4W) or at Weeks 0, 4, and then Q8W)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 739

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 739
Study: 39494083

Group type: EXPERIMENTAL
Intervention: Assessment at T2 (2020-2021) using WHOQOL-BREF
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Assessment at T1 (2015-2016) and T2 (2020-2021) using WHOQOL-BREF
Number of subjects: 284
Study: 39494309

Group type: EXPERIMENTAL
Intervention: Personalized nutritional intervention using the Nutrition Care Process (NCP) model
Number of subjects: 2050

Group type: EXPERIMENTAL
Intervention: Nutritional diagnoses in the intake domain
Number of subjects: 2050
Study: 39494565

Group type: EXPERIMENTAL
Intervention: Aerobic training (3 times/week, 65%-85% peak oxygen uptake)
Number of subjects: 54
Study: 39494577

Group type: EXPERIMENTAL
Intervention: OCT guidance
Number of subjects: 588

Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 588
Study: 39494607

Group type: EXPERIMENTAL
Intervention: Oral iron replacement therapy (IRT) with probiotics, specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral iron replacement therapy (IRT) without probiotics, specific dosage and duration not mentioned.
Number of subjects: 0
Study: 39494843

Group type: EXPERIMENTAL
Intervention: Intervention villages implementing strategies developed in Phase 2 for 1 year
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care in control villages
Number of subjects: 48
Study: 39495056

Group type: EXPERIMENTAL
Intervention: Vitros NT-proBNP II assay
Number of subjects: 2200
Study: 39495136

Group type: EXPERIMENTAL
Intervention: Semi-annual screening with ultrasound ± alpha-fetoprotein (arm A)
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Semi-annual screening with GALAD (arm B)
Number of subjects: 5500
Study: 39495140

Group type: COMPARATOR
Intervention: ECC5004 (1-300 mg single doses in healthy volunteers; 5, 10, 30, and 50 mg multiple daily doses in patients with T2DM for 28 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECC5004
Number of subjects: 0
Study: 39495154

Group type: EXPERIMENTAL
Intervention: Lorecivivint (LOR) 0.07 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39495175

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy (NAIC)
Number of subjects: 75
Study: 39495243

Group type: EXPERIMENTAL
Intervention: Inappropriate DOAC dosing
Number of subjects: 432

Group type: COMPARATOR
Intervention: Appropriate DOAC dosing
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Non-rivaroxaban DOACs
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Old age
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 432
Study: 39495467

Group type: EXPERIMENTAL
Intervention: Mitiperstat 2.5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mitiperstat 5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mitiperstat 10 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mitiperstat (all doses)
Number of subjects: 32
Study: 39495531

Group type: EXPERIMENTAL
Intervention: Deferiprone 15 mg/kg twice a day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 39495569

Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no anticoagulation)
Number of subjects: 0
Study: 39495582

Group type: EXPERIMENTAL
Intervention: Higher risk interventions (sphincterotomy, sphincteroplasty, precut sphincterotomy, and/or needle-knife access)
Number of subjects: 8517

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 8517

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 8517

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 8517

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8517

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 8517

Group type: EXPERIMENTAL
Intervention: Sphincterotomy
Number of subjects: 8517

Group type: EXPERIMENTAL
Intervention: CSPEB
Number of subjects: 8517
Study: 39495835

Group type: EXPERIMENTAL
Intervention: Echocardiographic parameters
Number of subjects: 0
Study: 39495965

Group type: EXPERIMENTAL
Intervention: Survodutide (3.6 or 6.0 mg, once-weekly subcutaneous injections)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo (once-weekly subcutaneous injections)
Number of subjects: 726
Study: 39495999

Group type: EXPERIMENTAL
Intervention: Video Conference (VC) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Video-Based Home Exercise (VBHE) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of VC vs VBHE
Number of subjects: 30
Study: 39496043

Group type: EXPERIMENTAL
Intervention: Low-volume training resistance training (LVT; n=15, 3 sessions of 12 exercises per week)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate-volume training resistance training (MVT; n=15; 4 sessions of 12 exercises per week)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-volume training resistance training (HVT; n=15; 5 sessions of 12 exercises per week)
Number of subjects: 45
Study: 39496135

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 6
Study: 39496153

Group type: EXPERIMENTAL
Intervention: Heat index between over 27°C and 32°C
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Heat index over 32°C
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lower health literacy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Better self-reported protective behavior
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lower self-efficacy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Higher somatosensory amplification
Number of subjects: 61
Study: 39496199

Group type: EXPERIMENTAL
Intervention: Experimental lozenges containing laccase enzyme and green coffee extract (with flavor)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Experimental lozenges containing laccase enzyme and green coffee extract (without flavor)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 156

Group type: COMPARATOR
Intervention: No-product control
Number of subjects: 156
Study: 39496364

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with biofeedback and home training for 6 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention during the 6 months).
Number of subjects: 0
Study: 39496367

Group type: EXPERIMENTAL
Intervention: ISMiHealth software intervention with screening recommendations for infectious diseases and FGM.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Current routine practice in control centres.
Number of subjects: 35
Study: 39497010

Group type: EXPERIMENTAL
Intervention: Lateral lymph node dissection (LLND) in non-CRT patients
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Lateral lymph node dissection (LLND) in nCRT patients
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Pathological obturator node metastasis
Number of subjects: 566
Study: 39497088

Group type: EXPERIMENTAL
Intervention: ASD patients
Number of subjects: 100
Study: 39497092

Group type: EXPERIMENTAL
Intervention: High bronchodilator response (BDR) group (N = 277)
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Low bronchodilator response (BDR) group (N = 278)
Number of subjects: 1134

Group type: COMPARATOR
Intervention: LOCCS cohort (adult asthma cohort)
Number of subjects: 1134
Study: 39497332

Group type: EXPERIMENTAL
Intervention: Low-dose cone-beam computed tomography (CBCT) protocol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard-dose cone-beam computed tomography (CBCT) protocol
Number of subjects: 11
Study: 39497468

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide (≥20% weight reduction)
Number of subjects: 0
Study: 39497537

Group type: EXPERIMENTAL
Intervention: Injectable hormonal contraception, frequency of sex in the prior 3 months, residing in a community with HIV prevalence of 29% or higher (females)
Number of subjects: 8551

Group type: EXPERIMENTAL
Intervention: Non-long-term relationships with the most recent partner, community HIV prevalence of 34% or higher (males)
Number of subjects: 8551
Study: 39497616

Group type: EXPERIMENTAL
Intervention: Intravitreal pegcetacoplan 15 mg monthly
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: Intravitreal pegcetacoplan 15 mg every other month (EOM)
Number of subjects: 1501

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1501
Study: 39497751

Group type: EXPERIMENTAL
Intervention: Crizanlizumab 5.0 mg/kg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Crizanlizumab 7.5 mg/kg
Number of subjects: 57
Study: 39497836

Group type: EXPERIMENTAL
Intervention: Cranial surgery (260 subjects; 65% decompressive craniectomy, 23% craniotomy, 12% other surgery)
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Earlier time-to-craniectomy
Number of subjects: 2032
Study: 39497947

Group type: EXPERIMENTAL
Intervention: 3-month TTR 110-140 mm Hg
Number of subjects: 7134

Group type: EXPERIMENTAL
Intervention: 3-month TTR >0.65
Number of subjects: 7134

Group type: EXPERIMENTAL
Intervention: 3-month TTR index cutoff of 0.65
Number of subjects: 7134
Study: 39498312

Group type: EXPERIMENTAL
Intervention: Heart-Smile Training (HST) intervention group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 50
Study: 39498340

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg every other day) combined with csDMARDs for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo combined with csDMARDs for 6 months
Number of subjects: 60
Study: 39498349

Group type: EXPERIMENTAL
Intervention: New-generation mask (AirFit F30i or AirFit N30i)
Number of subjects: 215
Study: 39498443

Group type: EXPERIMENTAL
Intervention: AAC + LPO (Ask-Advise-Connect + Longitudinal Proactive Outreach)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: AAC (Ask-Advise-Connect)
Number of subjects: 2000
Study: 39498574

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 4441

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 4441
Study: 39498781

Group type: EXPERIMENTAL
Intervention: Galantamine (8 to 12 mg twice daily, total 16 mg to 24 mg/day)
Number of subjects: 10990
Study: 39498822

Group type: EXPERIMENTAL
Intervention: Low dialysate sodium (< 138 mM)
Number of subjects: 509
Study: 39499011

Group type: EXPERIMENTAL
Intervention: 68 Ga-HBED-CC-exendin-4
Number of subjects: 19

Group type: COMPARATOR
Intervention: 68 Ga-NOTA-exendin-4
Number of subjects: 19
Study: 39499142

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg twice daily for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 39499299

Group type: EXPERIMENTAL
Intervention: Obinutuzumab and idelalisib
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 38
Study: 39499309

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 107
Study: 39499373

Group type: EXPERIMENTAL
Intervention: SP-CNN framework for segmenting and modeling lenticulostriate arteries (LSAs)
Number of subjects: 50
Study: 39499377

Group type: EXPERIMENTAL
Intervention: Totally laparoscopic distal gastrectomy (TLDG)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 442
Study: 39499437

Group type: EXPERIMENTAL
Intervention: Individual patient education sessions (2 sessions)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of individual session at baseline and group session 3 months later
Number of subjects: 120
Study: 39499486

Group type: EXPERIMENTAL
Intervention: Nivolumab and bevacizumab
Number of subjects: 39
Study: 39499492

Group type: EXPERIMENTAL
Intervention: pembrolizumab + chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 0
Study: 39499517

Group type: EXPERIMENTAL
Intervention: PFMT with home-based pressure-mediated biofeedback device
Number of subjects: 452

Group type: COMPARATOR
Intervention: Home-based PFMT
Number of subjects: 452
Study: 39499551

Group type: EXPERIMENTAL
Intervention: Behavior change communication mobile messages over a 14-day period
Number of subjects: 100

Group type: COMPARATOR
Intervention: e-voucher for LLINs
Number of subjects: 100
Study: 39499912

Group type: EXPERIMENTAL
Intervention: Storm-Heroes (social game)
Number of subjects: 79

Group type: COMPARATOR
Intervention: A Smoking Prevention Interactive Experience (ASPIRE; nonsocial program)
Number of subjects: 79
Study: 39499920

Group type: EXPERIMENTAL
Intervention: High effort resistance exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low effort resistance exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sedentary (control) session
Number of subjects: 15
Study: 39499921

Group type: EXPERIMENTAL
Intervention: CHALO! 2.0 (a theory-based multilevel intervention delivered in part through WhatsApp)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Attention-matched SMT-based control (including a digital coupon for free HIV testing)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Digital coupon-only control
Number of subjects: 1000
Study: 39500096

Group type: EXPERIMENTAL
Intervention: Community-based mental healthcare (CBMHC) service package
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Routine maternal care
Number of subjects: 1215
Study: 39500130

Group type: EXPERIMENTAL
Intervention: C-peptide levels
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: BMI increase
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Baseline prevalence of IAH
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Incidence of new IAH
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Incidence of reversal of IAH
Number of subjects: 431
Study: 39500299

Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioural intervention (combination of a web-based program and sessions with a psychologist)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Guided web-based intervention (active control group)
Number of subjects: 34
Study: 39500494

Group type: EXPERIMENTAL
Intervention: CytoSorb therapy
Number of subjects: 0
Study: 39500603

Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase after mechanical thrombectomy (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 0
Study: 39500789

Group type: EXPERIMENTAL
Intervention: nnUNet AI model
Number of subjects: 0
Study: 39500883

Group type: EXPERIMENTAL
Intervention: JMT103 (2 mg/kg) administered subcutaneously every four weeks, with loading doses on days 8 and 15.
Number of subjects: 139
Study: 39500896

Group type: EXPERIMENTAL
Intervention: Vincristine treatment
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1100